07/11/2022
In this podcast, Thomas Keller, MD, discusses his analysis on the association of guideline-recommended chronic obstructive pulmonary disease inhaler regimens with mortality, respiratory exacerbations, and quality of life and what the findings suggest about the need to reevaluate the effectiveness of risk stratification model-based inhaled treatment strategies.
Additional Resources:
- Keller T, Spece LJ, Donovan LM, et al. Association of guideline-recommended COPD inhaler regimens with mortality, respiratory exacerbations, and quality of life: a secondary analysis of the Long-Term Oxygen Treatment Trial. CHEST. pii:S0012-3692(20):30593-30596. doi:10.1016/j.chest.2020.02.073
- Yusen RD, Criner GJ, Sternberg AL, et al; LOTT Research Group. The Long-Term Oxygen Treatment Trial for chronic obstructive pulmonary disease: rationale, design, and lessons learned. Ann Am Thorac Soc. 2018;15(1):89-101. doi:10.1513/AnnalsATS.201705-374SD
- Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management, and prevention: a guide for health care professionals. 2017. Accessed May 5, 2020. https://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf
Thomas Keller, MD, is a fellow of pulmonary and critical care medicine at the University of Washington in Seattle, Washington.
